Roivant Sciences Ltd. filings document material events for a Nasdaq-listed Bermuda biopharmaceutical company with common shares registered under the ticker ROIV. The company’s recent Form 8-K disclosures cover quarterly financial results, preliminary liquidity information, share repurchases, Regulation FD updates and exhibits tied to clinical programs at subsidiaries such as Priovant Therapeutics.
Its filings also record material definitive agreements and amendments, including the Genevant Sciences settlement agreement involving lipid nanoparticle delivery technology, as well as shareholder voting results from the annual general meeting. Governance disclosures include director elections, auditor ratification and other proxy-related voting matters, while clinical exhibits describe programs such as brepocitinib in autoimmune and inflammatory diseases.
Roivant Sciences (ROIV) Form 4, filed 1 Aug 2025, discloses a large equity grant to President & Vant Chair Frank Torti. On 30 Jul 2025 he received (i) 1,836,547 time-based RSUs that vest 20 % after one year and quarterly thereafter, and (ii) 11,900,000 performance-based PSUs split into six price-hurdle tranches ($15–$30). Each tranche vests only after both a share-price test (30-day VWAP before 26 Jul 2029) and one additional year of service, followed by a two-year holding lock-up. The award was granted at $0 cost; no open-market buying occurred.
Post-grant, Torti’s beneficial ownership rises to 13,736,547 common shares, all held directly. While the structure tightly links vesting to long-term price performance, full issuance would add material dilution if all hurdles are met.
Roivant Sciences Ltd. (ROIV) – Form 4 filing: President & Immunovant CEO Eric Venker reported an equity award on 30 Jul 2025. The grant comprises 198,413 restricted stock units (RSUs) for common shares at a cost basis of $0. Vesting begins 20 May 2025, with 25 % vesting on the first anniversary and the balance in 12 equal quarterly tranches, contingent upon continued service.
Post-grant, Venker’s direct beneficial ownership rises to 1,660,636 common shares. The filing contains no open-market purchases or sales; therefore, it signals executive retention rather than a valuation view. The transaction represents routine equity compensation and has minimal immediate dilution or cash-flow impact for shareholders.
Roivant Sciences (ROIV) – Form 4 filing (30 Jul 2025)
CFO Richard Pulik reported an automatic disposition of 1,919 common shares on 28 Jul 2025 at an implied price of $11.35. The transaction is coded “F”, indicating the issuer withheld shares to cover taxes due upon the vesting of previously granted restricted stock units (RSUs); no open-market sale occurred. After the net-settlement, Pulik retains 397,553 shares, so the shares surrendered equal roughly 0.5 % of his post-transaction holdings. Because the activity is tax-related and immaterial to overall ownership, it is typically viewed as routine rather than a directional signal on the company’s prospects.
Roivant Sciences (ROIV) – Form 3. President & Vant Chair Frank Torti has filed his initial beneficial-ownership report covering 10.27 million common shares underlying stock options. Exercise prices range from $3.85 to $13.07 with expiry dates between 2028-2032. The largest tranche is 6.03 million options at $3.85 that vest 25% on 20-Apr-2023 and monthly thereafter; all other grants are already fully vested. No non-derivative share holdings were disclosed. The filing confirms Torti’s officer status and records his equity incentives for Section 16 compliance.